Results 171 to 180 of about 191,380 (292)

Pediatric liver transplantation: Prospects for linear growth [PDF]

open access: yes, 1987
Gartner, JC   +4 more
core  

Differentiation Syndrome and Sweet Syndrome‐Like Overlap Following Venetoclax–Azacytidine and G‐CSF Therapy

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Differentiation syndrome (DS) and Sweet syndrome (SS) are inflammatory complications mediated by cytokine dysregulation, classically associated with therapies that promote myeloid differentiation or cytokine release. While DS has been primarily linked to all‐trans retinoic acid (ATRA) and IDH inhibitors, recent evidence suggests that ...
Katerina Grafanaki   +6 more
wiley   +1 more source

Hell's Itch: A Self‐Case Report

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Hell's itch is a severely distressing dermatological condition characterized by the onset of incessant itching and intolerable pain 2–3 days post‐sunburn. It is underdiagnosed and underreported, and no definitive management framework has yet been developed.
Kai Peter Moors, Willem I. Visser
wiley   +1 more source

Liver transplantation, 1980, with particular reference to cyclosporin-A. [PDF]

open access: yes, 1981
Iwatsuki, S   +6 more
core  

Prognostic Value of the C‐PLAN Index in Advanced Esophageal Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT This study evaluated the prognostic value of the C‐PLAN index in advanced esophageal squamous cell carcinoma (ESCC) patients receiving immune checkpoint inhibitor (ICI) therapy. A retrospective analysis of 241 eligible patients treated during February 2020 to January 2023 was conducted.
Yi Zhou   +5 more
wiley   +1 more source

Fat Mass and Obesity‐Associated Protein Contributes to Tumorigenesis and Drug Resistance of Diffuse Large B‐Cell Lymphoma by Suppressing N6‐Methyladenosine Methylation of Myc

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Ibrutinib resistance remains a major obstacle in the treatment of diffuse large B‐cell lymphoma (DLBCL). Fat mass and obesity‐associated protein (FTO) has been implicated in drug resistance through its regulation of N6‐methyladenosine (m6A) modifications; however, whether FTO mediates ibrutinib resistance in DLBCL remains unclear.
Ting‐Ting Lu   +5 more
wiley   +1 more source

Effectiveness and safety analysis of initial treatment with belimumab in childhood-onset systemic lupus erythematosus. [PDF]

open access: yesFront Immunol
Li Y   +14 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy